Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Neurocrine Biosciences, Inc. (NBIX)

122.15   3.18 (2.67%) 11-25 13:00
Open: 118.76 Pre. Close: 118.97
High: 122.18 Low: 117.62
Volume: 283,681 Market Cap: 11,743(M)

Technical analysis

as of: 2022-11-25 1:59:00 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 147.15     One year: 171.87
Support: Support1: 114.43    Support2: 107.29
Resistance: Resistance1: 125.98    Resistance2: 147.15
Pivot: 119.65
Moving Average: MA(5): 120.07     MA(20): 119.54
MA(100): 106.83     MA(250): 95.63
MACD: MACD(12,26): 1.8     Signal(9): 2.1
Stochastic oscillator: %K(14,3): 63.7     %D(3): 58.8
RSI: RSI(14): 58.6
52-week: High: 125.98  Low: 71.87
Average Vol(K): 3-Month: 823 (K)  10-Days: 787 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ NBIX ] has closed below upper band by 30.5%. Bollinger Bands are 22.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 122.37 - 122.99 122.99 - 123.49
Low: 117.52 - 118.17 118.17 - 118.71
Close: 118.03 - 119.04 119.04 - 119.87

Company Description

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Headline News

Fri, 25 Nov 2022
Hot Biotech Stocks Rise Into Leadership; Pass Buy Points Or Build Bases - Investor's Business Daily

Fri, 25 Nov 2022
Futures: 5 Stocks Near Buys; Tesla FSD Beta Expands Widely - Investor's Business Daily

Thu, 17 Nov 2022
Stock Market Recovers After Early Downdraft; NBIX, Lululemon, SHLS Show Strength - Video - IBD - Investor's Business Daily

Wed, 16 Nov 2022
Should You Add Neurocrine Biosciences, Inc. (NBIX) Stock to Your Portfolio Wednesday? - InvestorsObserver

Wed, 09 Nov 2022
Looking Into Neurocrine Biosciences's Return On Capital Employed - Neurocrine Biosciences (NASDAQ:NBIX) - Benzinga

Thu, 03 Nov 2022
Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022 - PR Newswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 96 (M)
Shares Float 95 (M)
% Held by Insiders 1.1 (%)
% Held by Institutions 96.6 (%)
Shares Short 2,630 (K)
Shares Short P.Month 2,660 (K)

Stock Financials

EPS 0.58
EPS Est Next Qtl -0.41
EPS Est This Year -2.46
EPS Est Next Year -1.71
Book Value (p.s.) 16.06
Profit Margin (%) 4.1
Operating Margin (%) 15
Return on Assets (ttm) 6.3
Return on Equity (ttm) 4
Qtrly Rev. Growth 31
Gross Profit (p.s.) 8.22
Sales Per Share 14.45
EBITDA (p.s.) 2.32
Qtrly Earnings Growth 200
Operating Cash Flow 201 (M)
Levered Free Cash Flow 206 (M)

Stock Valuations

PE Ratio 207.03
PEG Ratio -23.9
Price to Book value 7.6
Price to Sales 8.44
Price to Cash Flow 58.53

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date 1995-12-28
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.